University of Pennsylvania

Cedars-sinai Medical Center

Leland Stanford Junior University

Cephalon, Inc.

Other

Ramachandran Murali

Mark I Greene

Hongtao Zhang

Alan Berezov

Stephen Pandol

Mark Richter

Jinqiu Chen

Qingdu Liu

Raphael M Ottenbrite

Masahiko Kinosaki

Xin Cheng

Michael R Freeman

Sungyong You

Mouad Edderkaoui

Xiaomin Song

Masahide Tone

Mirja Rotinen

Akihiro Hasegawa

Donald O'Rourke

Yingxin Xiao

Aida Habtezion

Byeong-Woo Park

Qiang Wang

Youhai H Chen

Roland E Baron

John G Monroe

Elad Katz

Yingxin Xiaio

Jing Sun

William Carle Horne

Hirotaka Kanzaki

Kazuhiro Aoki

Wataru Takasaki

Donald M O'Rourke

Raphael Ottenbrite

Stephen J Pandol

Mark I Greeene

Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of cancer in the subject.

Compositions and methods for treating cancer

The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.

Compositions and methods for treating fibrosis

Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of neuroblastoma, small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), large-cell carcinoma (LCC), squamous cell carcinoma (SqCC), and/or adenocarcinoma (AC) in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of neuroblastoma, small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), large-cell carcinoma (LCC), squamous cell carcinoma (SqCC), and/or adenocarcinoma (AC) in the subject.

The invention provides methods and agents that modulate RelA activity. These methods and modulators of RelA activity can be used to treat cancer progression of basal-like breast cancer, such as triple-negative breast cancer.

Methods and use of compounds that bind to RelA of NF-kB

The invention describes compounds that inhibit both HDAC and GSK3&#x3b2; (i.e., HDAC/GSK3&#x3b2; dual inhibitors). The invention further describes compositions containing these HDAC/GSK3&#x3b2; dual inhibitors, as well as methods and kits using these HDAC/GSK3&#x3b2; dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3&#x3b2; to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3&#x3b2;. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

Compositions and methods for treating cancers

Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.

Antigen-binding proteins comprising recombinant protein scaffolds

The present invention relates to compounds of formula (I) that are inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-&#x3b1; mediated conditions: Formula (I)

Inhibitors of the tumor necrosis factor receptor complex

This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor.

Methods and use of compounds that bind to HER2/neu receptor complex

The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-&#x3b1; mediated conditions.

Tumor necrosis factor inhibitors

This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor.

Methods and use of compounds that bind to Her2/neu receptor complex

Growing community of inventors

Swarthmore, PA, United States of America

Ramachandran Murali